HUTCHMED (China) Ltd (HCM) Form 6-K — Aug 31, 2026
HUTCHMED announced positive high-level results from the SANOVO Phase III trial in China, in which ORPATHYS (savolitinib) plus TAGRISSO (osimertinib) demonstrated a statistically significant and highly clinically meaningful improvement in progression-free survival versus TAGRISSO alone in treatment-naive patients with MET-overexpressing, EGFR-mutated locally advanced or metastatic lung cancer, in both the high MET and intention-to-treat populations. The all-oral combination also showed very encouraging clinical benefit in overall survival as a secondary endpoint, and the trial will continue follow-up.
Key figures
- Trial Phase
- Phase III
- Orpathys Dose
- 300/200 mg twice daily (body-weight based)
- Tagrisso Dose
- 80 mg once daily
- Trial Setting
- treatment-naive locally advanced or metastatic NSCLC with EGFR mutation and MET overexpression (China)
- Randomization
- 1:1
- Trial Patients
- 326
- Trial Identifier
- NCT05009836
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.